Olema Pharmaceuticals Stock Today
| OLMA Stock | USD 10.12 0.40 4.12% |
Performance0 of 100
| Odds Of DistressOver 54
|
Olema Pharmaceuticals is trading at 10.12 as of the 1st of December 2024, a 4.12 percent increase since the beginning of the trading day. The stock's open price was 9.72. Olema Pharmaceuticals has 54 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Olema Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of November 2024 and ending today, the 1st of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of November 2020 | Category Healthcare | Classification Health Care |
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for womens cancers. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. The company has 57.3 M outstanding shares of which 8.56 M shares are now shorted by private and institutional investors with about 21.68 trading days to cover. More on Olema Pharmaceuticals
Moving against Olema Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Olema Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsOlema Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Olema Pharmaceuticals' financial leverage. It provides some insight into what part of Olema Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Olema Pharmaceuticals (OLMA) is traded on NASDAQ Exchange in USA. It is located in 780 Brannan Street, San Francisco, CA, United States, 94103 and employs 74 people. Olema Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 579.85 M. Olema Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 57.3 M outstanding shares of which 8.56 M shares are now shorted by private and institutional investors with about 21.68 trading days to cover.
Olema Pharmaceuticals currently holds about 240.71 M in cash with (83.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.01.
Check Olema Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Olema Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Olema Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Olema Pharmaceuticals. Please pay attention to any change in the institutional holdings of Olema Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Olema Ownership Details
Olema Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Citadel Advisors Llc | 2024-09-30 | 1.3 M | |
| Candriam Luxembourg S.c.a. | 2024-06-30 | 1.1 M | |
| Polar Capital Holdings Plc | 2024-06-30 | 1000 K | |
| Geode Capital Management, Llc | 2024-09-30 | 934.9 K | |
| Wellington Management Company Llp | 2024-06-30 | 905.3 K | |
| Woodline Partners Lp | 2024-06-30 | 852.6 K | |
| Victory Capital Management Inc. | 2024-09-30 | 851.5 K | |
| Great Point Partners Llc | 2024-06-30 | 796.9 K | |
| Balyasny Asset Management Llc | 2024-09-30 | 709.1 K | |
| Bvf Inc | 2024-09-30 | 9.1 M | |
| Logos Global Management Lp | 2024-06-30 | 6.4 M |
Olema Pharmaceuticals Historical Income Statement
Olema Stock Against Markets
Olema Pharmaceuticals Corporate Management
| JD Moriarty | Corporate Secretary | Profile | |
| Peter Kushner | CoFounder Fellow | Profile | |
| PharmD Faltaos | VP Pharmacology | Profile | |
| Kinney Horn | Chief Officer | Profile | |
| Cyrus Harmon | Chief Director | Profile | |
| Courtney Dugan | VP Communications | Profile | |
| John Moriarty | Chief VP | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Olema Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. If investors know Olema will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Olema Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.28) | Return On Assets (0.32) | Return On Equity (0.52) |
The market value of Olema Pharmaceuticals is measured differently than its book value, which is the value of Olema that is recorded on the company's balance sheet. Investors also form their own opinion of Olema Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Olema Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Olema Pharmaceuticals' market value can be influenced by many factors that don't directly affect Olema Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Olema Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Olema Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.